Assessing iron overload: Are we there yet?

Clinical Cancer Research

Volumn 18, Issue 23, 2012, Pages 6395-6397

  Kruger, Paul C ^a   Leahy, Michael F ^a,b   Olynyk, John K ^a,b,c,d  

^a FREMANTLE HOSPITAL   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c CURTIN UNIVERSITY   (Australia)

^d MURDOCH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; FERRITIN; IRON; TRANSFERRIN;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; ANEMIA; BLOOD TRANSFUSION; FERRITIN BLOOD LEVEL; HEMATOLOGIC MALIGNANCY; HUMAN; IRON BLOOD LEVEL; IRON OVERLOAD; IRON STORAGE; LIVER BIOPSY; LIVER LEVEL; MORBIDITY; MORTALITY; MYELODYSPLASTIC SYNDROME; NOTE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL;

FEMALE; HUMANS; IRON; IRON OVERLOAD; LEUKEMIA, MYELOID, ACUTE; LIVER; MAGNETIC RESONANCE IMAGING; MALE; MYELODYSPLASTIC SYNDROMES;

EID: 84870354744     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-2881     Document Type: Note

References (12)

1. Wermke M, Schmidt A, Middeke JM, Sockel K, von Bonin M, Schonefeldt C, et al. MRI-based liver iron content predicts for non-relapse mortality in MDS and AML patients undergoing allogeneic stem cell transplantation. Clin Cancer Res 2012;18:6460-8.
2. de Witte T. The role of iron in patients after bone marrow transplantation. Blood Rev 2008;22(Suppl. 2):S22-28.
3. Virtanen JM, Remes KJ, Itala-Remes MA, Saunavaara JP, Komu ME, Partanen AM, et al. The relationship between cardiac and liver iron evaluated by MR imaging in haematological malignancies and chronic liver disease. Blood Cancer J 2012;2:e49.
4. Gandon Y, Olivie D, Guyader D, Aube C, Oberti F, Sebille V, et al. Noninvasive assessment of hepatic iron stores by MRI. Lancet 2004; 363:357-62. (Pubitemid 38169542)
5. St Pierre TG, Clark PR, Chua-anusorn W, Fleming AJ, Jeffrey GP, Olynyk JK, et al. Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. Blood 2005;105: 855-61. (Pubitemid 40070775)
6. Echeverria JMA, Castiella A, Emparanza JI. Quantification of iron concentration in the liver by MRI. Insights Imaging 2012;3: 173-80.
7. Olynyk JK, Gan E, Tan T. Predicting iron overload in hyperferritinemia. Clin Gastroenterol Hepatol 2009;7:359-62.
8. Bird RJ, Kenealy M, Forsyth C, Wellwood J, Leahy MF, Seymour JF, et al. Whenshould iron chelation therapy be considered in patients with myelodysplasia and other bone marrow failure syndromes with iron overload? Intern Med J 2012;42:450-5.
9. Bazuave GN, Buser A, Gerull S, Tichelli A, Stern M. Prognostic impact of iron parameters in patients undergoing allo-SCT. Bone Marrow Transplant 2012;47:60-4.
10. Armand P, Kim HT, Cutler CS, Ho VT, Koreth J, Alyea EP, et al. Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation. Blood 2007;109:4586-8. (Pubitemid 46743431)
11. Berger MD, Gerber B, Arn K, Senn O, Schanz U, Stussi G. Significant reduction of red blood cell transfusion requirements by changing from a double-unit to a single-unit transfusion policy in patients receiving intensive chemotherapy or stem cell transplantation. Haematologica 2012;97:116-22.
12. Ferrari P, Kulkarni H, Dheda S, Betti S, Harrison C, St Pierre TG, et al. Serum iron markers are inadequate for guiding iron repletion in chronic kidney disease. Clin J Am Soc Nephrol 2011;6:77-83.